Immunoglobulin A Nephropathy Igan clinical trials

Explore recruiting immunoglobulin a nephropathy igan clinical trials.

Recruiting immunoglobulin a nephropathy igan studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immunoglobulin A Nephropathy Igan trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)

Germany, Portugal, Italy, Spain, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)

Netherlands, Belgium, Hungary, Spain, Austria, Poland +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)

Greece, Portugal, Spain, Croatia, Czechia, Belgium +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)

Poland, Portugal, Belgium, France, Germany, Lithuania +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER).

Norway, Latvia, Hungary, Poland, Austria, Belgium +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3, Multicenter, Open‑label Trial to Evaluate the Long‑term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy.

Spain, Belgium, Croatia, Czechia, France, Germany +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

Immunoglobulin A Nephropathy Igan trials by city

Immunoglobulin A Nephropathy Igan in Toronto Immunoglobulin A Nephropathy Igan in Vancouver Immunoglobulin A Nephropathy Igan in Montreal Immunoglobulin A Nephropathy Igan in Calgary Immunoglobulin A Nephropathy Igan in Edmonton Immunoglobulin A Nephropathy Igan in Ottawa Immunoglobulin A Nephropathy Igan in Winnipeg Immunoglobulin A Nephropathy Igan in Quebec City Immunoglobulin A Nephropathy Igan in Hamilton Immunoglobulin A Nephropathy Igan in Kitchener Immunoglobulin A Nephropathy Igan in London Immunoglobulin A Nephropathy Igan in Halifax Immunoglobulin A Nephropathy Igan in New York Immunoglobulin A Nephropathy Igan in Los Angeles Immunoglobulin A Nephropathy Igan in Chicago Immunoglobulin A Nephropathy Igan in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease